Cinpanemab

• UNSPSC Description:

  Cinpanemab (BIIB054) is a human-derived monoclonal antibody that binds to α-synuclein. Cinpanemab can be used for the research of Parkinson's disease[1][2].

• Target Antigen:

  α-synuclein

• Type:

  Inhibitory Antibodies

• Related Pathways:

  Neuronal Signaling

• Applications:

  Neuroscience-Neurodegeneration

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/cinpanemab.html

• Purity:

  98.82

• Solubility:

  H2O

• Smiles:

  [Cinpanemab]

• References & Citations:

  [1]Lang AE, et, al. Trial of Cinpanemab in Early Parkinson's Disease. N Engl J Med. 2022 Aug 4;387(5):408-420. |[2]Teng JS, et, al. Immunotherapies for Parkinson's Disease: Progression of Clinical Development. CNS Neurol Disord Drug Targets. 2021;20(9):802-813.

• Shipping Conditions:

  Dry Ice

• Storage Conditions:

  Store at -80°C for 2 years

• Clinical Information:

  Phase 2

• CAS Number:

  2094516-02-4